Pricing
  1. US-listed companies
  2. Tonix Pharmaceuticals Holding Corp.
  3. Financials
  4. Research & development

Tonix Pharmaceuticals Holding Corp. (TNXP)

Market cap
$122.55M
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202440-53.87%
Dec 31, 202387+5.84%
Dec 31, 202282+18.94%
Dec 31, 202169+90.39%
Dec 31, 202036+98.75%
Dec 31, 201918+36.35%
Dec 31, 201713-53.24%
Dec 31, 201629-19.63%
Dec 31, 201536+90.71%
Dec 31, 201419+102.69%
Dec 31, 20139+102.52%
Dec 31, 20125+132.34%
Dec 31, 20112

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat